SCHEMBL6699166

SCHEMBL6699166

O=C(/C=C/c1cccc(Cl)c1)c1ccccc1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.73
MAOA P21397 6/20 0.73
HSP90AA1 P07900 1/20 0.73
MAPT P10636 4/20 0.69
BCHE P06276 1/20 0.69
CYP2C19 P33261 1/20 0.69
AR P10275 1/20 0.67
KDM4E B2RXH2 2/20 0.66
MAPK1 P28482 2/20 0.66
KMT2A Q03164 2/20 0.66
GAA P10253 1/20 0.66
PTGS1 P23219 1/20 0.66
PTGS2 P35354 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
MYOC Q99972 1/20 0.66
CYP1A1 P04798 1/20 0.64
CYP1B1 Q16678 1/20 0.64
CYP1A2 P05177 1/20 0.61
CYP2C9 P11712 1/20 0.61
MEN1 O00255 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25243464 1.00 MAOB (0.73) MAOBMAOAHSP90AA1MAPTBCHE
SCHEMBL30384224 1.00 MAOB (0.73) MAOBMAOAHSP90AA1MAPTBCHE
SCHEMBL6699171 1.00 MAOB (0.73) MAOBMAOAHSP90AA1MAPTBCHE
SCHEMBL31233113 1.00 MAOB (0.73) MAOBMAOAHSP90AA1MAPTBCHE
SCHEMBL25207247 0.89 MAOB (0.84) MAOBMAOAHSP90AA1MAPTBCHE
SCHEMBL25202154 0.88 CYP1A1 (0.64) MAOBMAOAHSP90AA1MAPTAR
SCHEMBL25202013 0.85 MAOB (0.72) MAOBMAOAHSP90AA1MAPTCYP2C19
SCHEMBL30384325 0.85 MAOB (0.72) MAOBMAOAHSP90AA1MAPTCYP2C19
SCHEMBL129048 0.84 MAOB (1.00) MAOBMAOAHSP90AA1MAPTBCHE
SCHEMBL25188844 0.84 MAOB (1.00) MAOBMAOAHSP90AA1MAPTBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308624-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds NORTHWESTERN UNIVERSITY (US) 2019-06-04 US disclosed
US-20180099943-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds NORTHWESTERN UNIVERSITY 2018-04-12 US disclosed
US-9840487-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds NORTHWESTERN UNIVERSITY (US) 2017-12-12 US disclosed
US-20170217919-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds NORTHWESTERN UNIVERSITY 2017-08-03 US disclosed
US-9624190-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds NORTHWESTERN UNIVERSITY (US) 2017-04-18 US disclosed
US-20160221982-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds NORTHWESTERN UNIVERSITY 2016-08-04 US disclosed
US-9309217-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds NORTHWESTERN UNIVERSITY (US) 2016-04-12 US disclosed
US-20150315168-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-20150094331-A1 QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AUSPEX PHARMACEUTICALS, INC. (US) 2015-04-02 US disclosed
US-20040147597-A1 Anti-mycobacterium compositions and methods of preparing and using same ADVANCED LIFE SCIENCES, INC. 2004-07-29 US disclosed
US-6677350-B1 ADMINISTERING CHALCONE-LIKE VINYLCARBONYL COMPOUNDS TO PREVENT OR TREAT MYCOBACTERIUM INFECTIONS/TUBERCULOSIS ADVANCED LIFE SCIENCES, INC. 2004-01-13 US disclosed
EP-1217995-A2 ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME Advanced Life Sciences Inc. (US) 2002-07-03 EP disclosed
WO-2001021164-A2 ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME ADVANCED LIFE SCIENCES, INC. (US) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217919-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885HSP90AA1 4580/4885
US-20150094331-A1 QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 PLA2G12A, PLA2G4A, PLA2G2A MAOB 547/4885MAOA 476/4885HSP90AA1 2203/4885
US-20160221982-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885HSP90AA1 4580/4885
US-10308624-B2 Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885HSP90AA1 4580/4885
US-20150315168-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885HSP90AA1 4580/4885
US-20040147597-A1 Anti-mycobacterium compositions and methods of preparing and using same IMMT, CYP51A1, LSS MAOB 1715/4885MAOA 1739/4885HSP90AA1 1235/4885
US-20180099943-A1 Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds PNP, PPA1, CDS2 MAOB 927/4885MAOA 971/4885HSP90AA1 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.